IRVINE, Calif., Oct. 14, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application No. 17/381,005.… Continue reading Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001
